61 results on '"James, C. David"'
Search Results
2. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma
3. THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR
4. BSCI-23. TISSUE FACTOR SIGNALING ENHANCES METASTATIC BRAIN CANCER MALIGNANCY
5. DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG
6. STEM-28. TISSUE FACTOR PROMOTES THE GLIOMA STEM CELL PHENOTYPE, AND IS SUPPRESSED BY MUTANT IDH1
7. CSIG-15. SLFN5: A REPRESSOR OF INTERFERON-INDUCED SIGNALING THAT STIMULATES GLIOBLASTOMA CELL PROLIFERATION. SURVIVAL RESPONSES IN DIFFERENT XENOGRAFT GLIOBLASTOMA MOUSE MODELS
8. CSIG-18. MODELING TEMOZOLOMIDE RESISTANCE WITH GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS
9. TMOD-26. CYTOMEGALOVIRUS PROMOTES GLIOBLASTOMA GROWTH VIA PDGF-D DRIVEN PERICYTE RECRUITMENT AND ANGIOGENESIS
10. CSIG-35. MST4 PHOSPHORYLATION OF ATG4B REGULATES AUTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA
11. PDTM-05. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
12. GENE-17. TOP2B REGULATES CDK4 SPLICE VARIANTS IN GLIOMAS
13. DDIS-13. UNDERSTANDING GLIOBLASTOMA SUSCEPTIBILITY TO TOP2-TARGETING DRUGS FOR PERSONALIZED THERAPY
14. TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
15. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
16. IMMU-38. GLIOBLASTOMA-DERIVED IL-6 INDUCES IMMUNOSUPPRESSIVE PERIPHERAL MYELOID CELL PD-L1 EXPRESSION AND TUMOR PROGRESSION
17. TMOD-17. BRAIN TUMOR PATIENT DERIVED XENOGRAFT FROM LUNG TUMOR METASTASIS: ESTABLISHMENT AND CHARACTERIZATION
18. PDTM-02. NEXT-GENERATION SEQUENCING OF DIFFUSE INTRINSIC PONTINE GLIOMA CELLS REVEALS ALTERED EPIGENETIC REGULATION AND DISTINCT TUMOR SUBGROUPS
19. IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL
20. PDTM-44. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
21. IMMU-66. IDO1 EXPRESSION STRATIFIES PATIENT SURVIVAL AND IS REGULATED BY TUMOR INFILTRATING T CELLS IN HUMAN GLIOBLASTOMA
22. DRES-18. EZH2/PRC2-MEDIATED EPIGENETIC PLASTICITY PROMOTES THERAPEUTIC RESISTANCE BY REGULATING STAT3 ACTIVATION GENE NETWORK IN THE GLIOMA STEM CELLS
23. PDTM-28. TARGETED INHIBITION OF EZH2 AND BET BROMODOMAIN PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS
24. DIPG-24. EPIGENETIC ANALYSIS OF FORMALIN-FIXED PARAFFIN-EMBEDDED PEDIATRIC GLIOMA TISSUE
25. DIPG-25. IN VITRO AND IN VIVO ANALYSIS OF TENASCIN-C EXPRESSION IN PEDIATRIC BRAINSTEM GLIOMA
26. PDTB-14. INVESTIGATING HISTONE H3 POST-TRANSLATIONAL MODIFICATIONS USING PARAFFIN-EMBEDDED PEDIATRIC GLIOMA TISSUE SAMPLES
27. TMIC-15. MUTANT IDH1 SUPPRESSES THE PROCOAGULANT AND PROMALIGNANT EFFECTS OF TISSUE FACTOR IN GLIOMAS
28. PDTB-10. INHIBITION OF RADIATION-INDUCED DNA DAMAGE REPAIR MEDIATED CHROMATIN MODIFICATION BY HISTONE H3 DEMETHYLASE INHIBITOR IN PEDIATRIC BRAINSTEM GLIOMA
29. IMST-20. MAPK PATHWAY BLOCKADE PRIMES BRAFV600E MUTANT GLIOMA FOR IMMUNOTHERAPY
30. TMIC-24. THE CONTRIBUTION OF VASCULAR CO-OPTION AND TUMOR-DERIVED ENDOTHELIAL CELLS TO GBM RECURRENCE
31. STMC-16. EZH2-MEDIATED ARL13B REGULATE CILIOGENESIS IN GBM
32. TMOD-08. PDX MODELING OF RECURRENT GLIOBLASTOMA FOR TESTING SALVAGE THERAPIES
33. IMST-35. IDO1 AND TARGETED IMMUNOTHERAPY IN A MOUSE GLIOBLASTOMA MODEL
34. IMST-39. IDO1 IS PROGNOSTIC FOR GLIOBLASTOMA PATIENT SURVIVAL AND CENTRALLY CORRELATES WITH POTENTLY IMMUNOSUPPRESSIVE MEDIATORS
35. TMOD-26. DEVELOPING PATIENT-DERIVED XENOGRAFT MODELS OF METASTATIC CANCER TO THE BRAIN
36. PDTB-13. DETECTION OF HISTONE H3 MUTATIONS IN PEDIATRIC GLIOMA VIA TUMOR DNA DERIVED FROM CEREBROSPINAL FLUID
37. CSIG-08. A REGULATORY CIRCUIT OF miR-125b/miR-20b AND Wnt SIGNALING CONTROLS GBM PHENOTYPES THROUGH FZD6-MEDIATED PATHWAYS
38. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
39. CBIO-29TARGETING A Plk1-CONTROLLED POLARITY CHECKPOINT IN GLIOBLASTOMA MULTIFORME
40. MTR-07GLIOBLASTOMA ADAPTATION TO SUSTAINED cdk4/6 INHIBITION INVOLVES SUPPRESSION OF Rb EXPRESSION THROUGH HISTONE H3K4 MODIFICATION
41. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype
42. Targeting Wee1 for the treatment of pediatric high-grade gliomas
43. Aberrant miRNA expression in brain tumors: a subject attracting an increasing amount of attention
44. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
45. Expression of miR-124 inhibits growth of medulloblastoma cells
46. Clinical Stratification of Glioblastoma Based on Alterations in Retinoblastoma Tumor Suppressor Protein (RB1) and Association With the Proneural Subtype
47. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts
48. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
49. Focusing In, Broadening Our Reach
50. Mapping the Future of Neuro-oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.